Abstract

PARP inhibitors (PARPi) demonstrated improvement in progression-free survival (PFS) following first-line (1L) platinum-based chemotherapy (Pt-CT) for advanced ovarian carcinoma (OC) patients (pts). Here we describe real-world clinical outcomes in pts with de novo high-grade epithelial OC (HGEOC) eligible for niraparib per EMEA approval (PRIMA trial).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
ODALIE Study, a retrospective analysis of a real-life cohort of patients with de novo advanced high grade epithelial ovarian cancer treated with a first-line platinum- and taxane-based chemotherapy combined with bevacizumab.
Sarah Lagarde Bétrian ... Thierry Petit
Journal of Clinical Oncology | VOL. 40
Sarah Lagarde Bétrian, et. al.Sarah Lagarde Bétrian ... Thierry Petit
01 Jun 2022
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
Shaily Arora ...
The Oncologist | VOL. 26
Shaily Arora, et. al.Shaily Arora ...
20 Oct 2020
SCOUT-1: Prospective non-interventional study in patients with BRCA/HRD-tested ovarian cancer (OC) eligible for first-line (1L) platinum-based chemotherapy (NOGGO ov54).
Pauline Wimberger ... Matthias Rose
Journal of Clinical Oncology | VOL. 40
Pauline Wimberger, et. al.Pauline Wimberger ... Matthias Rose
01 Jun 2022
OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039)
Melissa Hardesty ... Debra Richardson
Gynecologic oncology | VOL. 166
Melissa Hardesty, et. al.Melissa Hardesty ... Debra Richardson
01 Aug 2022
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Efficacy of TIL Therapy in Advanced Cutaneous Melanoma in the Current Immuno-oncology Era: Updated Systematic Review and Meta-analysis
S Martín-Lluesma ... G Coukos
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
S Martín-Lluesma, et. al.S Martín-Lluesma ... G Coukos
23 Jul 2024
Exploiting the tumor microenvironment and tumor mechanobiology for the treatment of cancer cachexia
Kostas A Papavassiliou ... Athanasios G Papavassiliou
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
Kostas A Papavassiliou, et. al.Kostas A Papavassiliou ... Athanasios G Papavassiliou
23 Jul 2024
Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story
N Colombo ... M Jalving
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
N Colombo, et. al.N Colombo ... M Jalving
22 Jul 2024
Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
Rodrigo Sánchez-Bayona ... Mafalda Oliveira
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
Rodrigo Sánchez-Bayona, et. al.Rodrigo Sánchez-Bayona ... Mafalda Oliveira
22 Jul 2024
View more papers